23
Participants
Start Date
February 24, 2022
Primary Completion Date
November 21, 2023
Study Completion Date
November 21, 2023
MVA-SARS-2-ST
In this trial MVA-SARS-2-ST will be used. Each vial contains 1 x 107 IU/dose MVA-SARS-2-ST in 0.5 mL as active ingredient. The solution will be used for nebulization and direct administration to the respiratory tract.
Hannover Medical School ZKS - Early Clinical Trial Unit at CRC Hannover, Hanover
Collaborators (2)
German Center for Infection Research
OTHER
IDT Biologika
UNKNOWN
Universitätsklinikum Hamburg-Eppendorf
OTHER
Hannover Medical School
OTHER